Ryu KS - Search Results

1

The prognostic impact of duration of anemia during chemotherapy in advanced epithelial ovarian cancer.

Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH. Kim JH, et al. Among authors: ryu ks. Oncologist. 2011;16(8):1154-61. doi: 10.1634/theoncologist.2010-0236. Epub 2011 Jun 24. Oncologist. 2011. PMID: 21705663 Free PMC article.

2

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.

Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, Kim SJ, Lee JM. Ryu KS, et al. Gynecol Oncol. 2004 Aug;94(2):325-32. doi: 10.1016/j.ygyno.2004.05.044. Gynecol Oncol. 2004. PMID: 15297169

3

Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.

Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Ahn WS, Namkoong SE. Bae JH, et al. Among authors: ryu ks. Gynecol Oncol. 2007 Jul;106(1):193-200. doi: 10.1016/j.ygyno.2007.03.019. Epub 2007 Apr 26. Gynecol Oncol. 2007. PMID: 17466362

4

Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.

Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ. Kim JH, et al. Among authors: ryu ks. J Surg Oncol. 2010 Feb 1;101(2):149-55. doi: 10.1002/jso.21448. J Surg Oncol. 2010. PMID: 20035540 Clinical Trial.

5

Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution.

Lee CW, Song MJ, Park ST, Ki EY, Lee SJ, Lee KH, Ryu KS, Park JS, Hur SY. Lee CW, et al. Among authors: ryu ks. World J Surg Oncol. 2011 Oct 11;9:123. doi: 10.1186/1477-7819-9-123. World J Surg Oncol. 2011. PMID: 21988930 Free PMC article. Clinical Trial.

6

Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer.

Song MJ, Lee SH, Choi MR, Son HJ, Lee CW, Yoon JH, Park YG, Hur SY, Ryu KS, Lee JM. Song MJ, et al. Among authors: ryu ks. Eur J Gynaecol Oncol. 2013;34(2):148-51. Eur J Gynaecol Oncol. 2013. PMID: 23781586

7

Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers.

Ryu KS, Lee YS, Kim BK, Park YG, Kim YW, Hur SY, Kim TE, Kim IK, Kim JW. Ryu KS, et al. Exp Mol Med. 2001 Sep 30;33(3):136-44. doi: 10.1038/emm.2001.24. Exp Mol Med. 2001. PMID: 11642549

8

Identification of large-scale characteristic genes of Müllerian inhibiting substance in human ovarian cancer cells.

Nam SW, Jo YS, Eun JW, Song JY, Ryu KS, Lee JY, Lee JM, Maclaughlin DT, Kim JH. Nam SW, et al. Among authors: ryu ks. Int J Mol Med. 2009 May;23(5):589-96. doi: 10.3892/ijmm_00000168. Int J Mol Med. 2009. PMID: 19360316

9

Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers.

Le YS, Kim TE, Kim BK, Park YG, Kim GM, Jee SB, Ryu KS, Kim IK, Kim JW. Le YS, et al. Among authors: ryu ks. Exp Mol Med. 2002 Mar 31;34(1):18-26. doi: 10.1038/emm.2002.3. Exp Mol Med. 2002. PMID: 11989974

10

Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.

Song JY, Jo HH, Kim MR, Lew YO, Ryu KS, Cha JH, Kang CS, Donahoe PK, MacLaughlin DT, Kim JH. Song JY, et al. Among authors: ryu ks. Int J Oncol. 2012 Jun;40(6):2013-21. doi: 10.3892/ijo.2012.1370. Epub 2012 Feb 14. Int J Oncol. 2012. PMID: 22344630 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters